A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the
efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with
relapsed or refractory Hodgkin lymphoma.